Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disorders associated with insulin resistance syndrome

Details for Australian Patent Application No. 2004228125 (hide)

Owner POXEL SAS

Inventors Moinet, Gerard; Passemar, Thierry; Cravo, Daniel

Agent Davies Collison Cave

Pub. Number AU-B-2004228125

PCT Pub. Number WO2004/089917

Priority 0304486 10.04.03 FR

Filing date 6 April 2004

Wipo publication date 21 October 2004

Acceptance publication date 15 July 2010

International Classifications

C07D 251/10 (2006.01) Heterocyclic compounds containing 1,3,5-triazine rings

A61K 31/53 (2006.01) - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 5/50 (2006.01) Drugs for disorders of the endocrine system

A61P 33/06 (2006.01) Antiparasitic agents

Event Publications

1 December 2005 PCT application entered the National Phase

  PCT publication WO2004/089917 Priority application(s): WO2004/089917

16 July 2009 Assignment before Grant

  Merck Patent GmbH The application has been assigned to POXEL SAS

15 July 2010 Application Accepted

  Published as AU-B-2004228125

11 November 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004228138-Moulded bodies consisting of biological fibrous material and plastic

2004228124-Substituted pyrazole compounds